Evidence map›Paper›PMID 42290096›Full record

ArticleXenotransplantation

What's Hot and What's New in Xenotransplantation From the Young Investigator Committee of the IXA-Basic and Translational Science.

Corbin E Goerlich, Evelyn J Salvaris, Konrad Fischer, Antonio Citro, Alessia Giarraputo, Joseph Ladowski, Emilien Seizilles de Mazancourt, Liaoran Wang, Daniel Eisenson, Margaret R Connolly and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Xenotransplantation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Corbin E GoerlichStanford Hospital, Palo Alto, California, USA.ORCID https://orcid.org/0000-0001-9691-5835
Evelyn J SalvarisImmunology Research Centre, St Vincent's Hospital, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0001-7741-0743
Konrad FischerInstitute of Surgical Research, Walter Brendel Center of Experimental Medicine, University Hospital, LMU Munich, Munich, Germany.ORCID https://orcid.org/0000-0002-4926-7334
Antonio CitroSan Raffaele Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.ORCID https://orcid.org/0000-0002-0947-7687
Alessia GiarraputoDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0003-4070-7943
Joseph LadowskiDepartment of Surgery, Duke University School of Medicine, Durham, North Carolina, USA.ORCID https://orcid.org/0000-0002-6787-3725
Emilien Seizilles de MazancourtParis Institute of Transplantation and Organ Regeneration, Paris, France.ORCID https://orcid.org/0000-0002-2751-4111
Liaoran WangSecond Affiliated Hospital of Hainan Medical University, Haikou, China.ORCID https://orcid.org/0000-0003-1833-9494
Daniel EisensonJohns Hopkins Hospital, Baltimore, Maryland, USA.
Margaret R ConnollyHeart and Vascular Center, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Jeffrey SternDepartment of Surgery, NYU Langone, New York, New York, USA.
Alban LongchampDepartment of Surgery, Division of Transplant Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0002-1743-4935
Raphael P H MeierDepartment of Surgery, Division of Transplant Surgery, University of Maryland School of Medicine, Baltimore, Maryland, USA.ORCID https://orcid.org/0000-0001-9050-0436

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Xenotransplantation has been iteratively improved over the last decade in pre-clinical models, with first-in-human clinical trials underway. The 2025 IXA Congress in Geneva was held in parallel with meetings involving World Health Organization leaders to support the development of new guidance on xenotransplantation in this rapidly evolving field. Key scientific themes of the meeting included the introduction of multiple-gene edited pigs for xenotransplantation research and clinical trials, better characterization of innate and adaptive immune responses and xenograft preservation that optimizes ramifications of ischemia-reperfusion injury during implantation. This comes at a time when gene-edited pig organs are being used for human xenotransplantation, a development that demands safety, reproducibility, durability, and a clear mechanistic understanding of rejection and tolerance.

Indexed as

HeterograftsTransplantation, HeterologousAnimalsGraft RejectionHumansSwineTranslational Research, BiomedicalTranslational Science, Biomedical

Identifiers

PMID42290096
PMCPMC13266277

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.